Proteon Therapeutics Inc (PRTO) - Financial and Strategic SWOT Analysis Review

October 2019 | 48 pages | ID: PC4946A4722EN
GlobalData

Abstracts

Proteon Therapeutics Inc (PRTO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

• Business description – A detailed description of the company’s operations and business divisions.
• Corporate strategy – Analyst’s summarization of the company’s business strategy.
• SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
• Company history – Progression of key events associated with the company.
• Major products and services – A list of major products, services and brands of the company.
• Key competitors – A list of key competitors to the company.
• Key employees – A list of the key executives of the company.
• Executive biographies – A brief summary of the executives’ employment history.
• Key operational heads – A list of personnel heading key departments/functions.
• Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
• Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
• Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Proteon Therapeutics Inc (Proteon Therapeutics) is a late-stage biopharmaceutical company that develops pharmaceutical products for the treatment of renal and vascular diseases. The company develops investigational therapies to treat hemodialysis and peripheral artery disease patients. Its product candidate includes vonapanitase, an investigational drug intended to treat vessel injury that leads to blood vessel blockage and reduced blood flow. Proteon Therapeutics’ vonapanitase is under Phase 3 clinical study in hemodialysis vascular access. It owns and operates research facilities in Kansas City, Missouri. Proteon Therapeutics is headquartered in Waltham, Massachusetts, the US.

Proteon Therapeutics Inc Key Recent Developments

Sep 24,2019: Proteon Therapeutics to merge with ArTara Therapeutics
Aug 07,2019: Proteon Therapeutics announces second quarter 2019 financial results
May 08,2019: Proteon Therapeutics announces first quarter 2019 financial results
Apr 15,2019: Proteon Therapeutics announces review of potential strategic transactions
Mar 13,2019: Proteon Therapeutics announces fourth quarter and full-year 2018 financial results

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

• The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

• The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

• Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.

• Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

• Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Contents

SECTION 1 - ABOUT THE COMPANY

Proteon Therapeutics Inc - Key Facts
Proteon Therapeutics Inc - Key Employees
Proteon Therapeutics Inc - Key Employee Biographies
Proteon Therapeutics Inc - Major Products and Services
Proteon Therapeutics Inc - History
Proteon Therapeutics Inc - Company Statement
Proteon Therapeutics Inc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

Company Overview
Proteon Therapeutics Inc - Business Description
Proteon Therapeutics Inc - Corporate Strategy
Proteon Therapeutics Inc - SWOT Analysis
SWOT Analysis - Overview
Proteon Therapeutics Inc - Strengths
Proteon Therapeutics Inc - Weaknesses
Proteon Therapeutics Inc - Opportunities
Proteon Therapeutics Inc - Threats
Proteon Therapeutics Inc - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

Proteon Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Proteon Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019
Proteon Therapeutics Inc, Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

Sep 24, 2019: Proteon Therapeutics to merge with ArTara Therapeutics
Aug 07, 2019: Proteon Therapeutics announces second quarter 2019 financial results
May 08, 2019: Proteon Therapeutics announces first quarter 2019 financial results
Apr 15, 2019: Proteon Therapeutics announces review of potential strategic transactions
Mar 13, 2019: Proteon Therapeutics announces fourth quarter and full-year 2018 financial results
Nov 07, 2018: Proteon Therapeutics announces third quarter 2018 financial results
Aug 07, 2018: Proteon Therapeutics Announces Second Quarter 2018 Financial Results
May 09, 2018: Proteon Therapeutics Announces First Quarter 2018 Financial Results
Mar 14, 2018: Proteon Therapeutics Reports Fourth Quarter and Full-Year 2017 Financial Results

SECTION 6 – APPENDIX

Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Proteon Therapeutics Inc, Key Facts
Proteon Therapeutics Inc, Key Employees
Proteon Therapeutics Inc, Key Employee Biographies
Proteon Therapeutics Inc, Major Products and Services
Proteon Therapeutics Inc, History
Proteon Therapeutics Inc, Subsidiaries
Proteon Therapeutics Inc, Key Competitors
Proteon Therapeutics Inc, Ratios based on current share price
Proteon Therapeutics Inc, Annual Ratios
Proteon Therapeutics Inc, Annual Ratios (Cont...1)
Proteon Therapeutics Inc, Interim Ratios
Proteon Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Proteon Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019
Proteon Therapeutics Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List Of Figures

LIST OF FIGURES

Proteon Therapeutics Inc, Performance Chart (2014 - 2018)
Proteon Therapeutics Inc, Ratio Charts
Proteon Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Proteon Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2013 to YTD 2019

COMPANIES MENTIONED

Laminate Medical Technologies Ltd
Vascular Therapies Inc
Symic Bio Inc
Aplagon Oy
Phraxis, Inc.
Enceladus Pharmaceuticals BV
Stent Tek Ltd
CreatiVasc Medical LLC
Bioconnect Systems Inc